The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jan. 30, 7:24 AM

Slide #23. Radius Health, Inc. Secondary Offering

Company: Radius Health, Inc. (NASDAQ:RDUS)
Date announced: 1/20/2015
Shares Offered: 4,000,000
Date of Pricing: 1/22/2015
Price Per Share: $36.75
Secondary Offering Details: Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commencing an underwritten registered public offering of 3,500,000 shares of its common stock. The Company also expects to grant the underwriters an option to purchase up to an additional 525,000 shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 1/22 - Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it has priced its public offering of 4,000,000 shares of its common stock at a public offering price of $36.75 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 600,000 shares of its common stock, exercisable for 30 days.

Radius Health is a biopharmaceutical company focused on developing differentiated therapeutics for patients with osteoporosis as well as other endocrine-mediated diseases. Co.'s primary product candidate is abaloparatide (BA058), a bone anabolic for the treatment of osteoporosis delivered via subcutaneous injection, which Co. refers to as Abaloparatide-SC. Abaloparatide is a novel synthetic peptide analog of parathyroid hormone-related protein, or PTHrP, that Co. is developing as a bone anabolic treatment for osteoporosis. Co.'s clinical product portfolio also includes an oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader.
Open the RDUS Page at The Online Investor »

Company Name:  Radius Health Inc
Website:  www.radiuspharm.com
Sector:  Biotechnology
Number of ETFs Holding RDUS:  16
Total Market Value Held by ETFs:  $30.52M
Total Market Capitalization:  $1.46B
% of Market Cap. Held by ETFs:  2.09%
 

Open the RDUS Page at The Online Investor (in a new window) »

January 30, 2015    7:24 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.